DMTK DermTech Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DMTK

Price (delayed)

$2.47

Market cap

$76.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.9

Enterprise value

$80.44M

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech's mission is to transform ...

Highlights
The revenue has increased by 10% year-on-year
DermTech's debt has soared by 139% YoY
The gross margin has plunged by 86% YoY and by 78% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://dermtech.com
Peers: SERA SHC

Key stats

What are the main financial stats of DMTK
Market
Shares outstanding
31.09M
Market cap
$76.79M
Enterprise value
$80.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.7
Price to sales (P/S)
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.63
Earnings
Revenue
$14.28M
EBIT
-$117.85M
EBITDA
-$112.52M
Free cash flow
-$95.88M
Per share
EPS
-$3.9
Free cash flow per share
-$3.14
Book value per share
$3.53
Revenue per share
$0.47
TBVPS
$5.8
Balance sheet
Total assets
$177.12M
Total liabilities
$69.88M
Debt
$55.58M
Equity
$107.24M
Working capital
$96.25M
Liquidity
Debt to equity
0.52
Current ratio
6.96
Quick ratio
6.94
Net debt/EBITDA
-0.03
Margins
EBITDA margin
-788.1%
Gross margin
1%
Net margin
-825.4%
Operating margin
-840.6%
Efficiency
Return on assets
-59.7%
Return on equity
-82.2%
Return on invested capital
-89.1%
Return on capital employed
-73.2%
Return on sales
-825.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DMTK stock price

How has the DermTech stock price performed over time
Intraday
0.41%
1 week
7.86%
1 month
-29.83%
1 year
-62.23%
YTD
39.55%
QTD
-32.88%

Financial performance

How have DermTech's revenue and profit performed over time
Revenue
$14.28M
Gross profit
$139,000
Operating income
-$120.02M
Net income
-$117.85M
Gross margin
1%
Net margin
-825.4%
The gross margin has plunged by 86% YoY and by 78% from the previous quarter
DermTech's gross profit has shrunk by 85% YoY and by 79% QoQ
The operating income has contracted by 27% YoY
The net income has declined by 26% year-on-year

Growth

What is DermTech's growth rate over time

Valuation

What is DermTech stock price valuation
P/E
N/A
P/B
0.7
P/S
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.63
DermTech's EPS has decreased by 23% YoY
The price to book (P/B) is 93% lower than the 5-year quarterly average of 9.4 and 13% lower than the last 4 quarters average of 0.8
DermTech's equity has decreased by 47% YoY and by 19% from the previous quarter
The stock's P/S is 90% below its 5-year quarterly average of 55.1 and 32% below its last 4 quarters average of 7.8
The revenue has increased by 10% year-on-year

Efficiency

How efficient is DermTech business performance
The return on equity has dropped by 110% year-on-year and by 18% since the previous quarter
The company's return on assets has shrunk by 65% YoY and by 9% QoQ
DermTech's return on invested capital has increased by 37% YoY and by 11% QoQ
DermTech's ROS has decreased by 15% YoY and by 2.7% from the previous quarter

Dividends

What is DMTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DMTK.

Financial health

How did DermTech financials performed over time
The total assets is 153% greater than the total liabilities
DermTech's total liabilities has soared by 94% YoY
DermTech's current ratio has shrunk by 52% YoY and by 20% QoQ
DermTech's debt is 48% less than its equity
DermTech's debt has soared by 139% YoY
DermTech's equity has decreased by 47% YoY and by 19% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.